In this retrospective cohort study of patients in a real-world clinical setting, we identified a missense SNP rs7148 in the TMSB10/TRABD2A gene locus on chromosome 2 to be associated with a higher risk for CVAE in MM patients treated with CFZ. This evidence concerns the gene TRABD2A and Miyoshi myopathy.